In addition to MDS, sAML, and MPNs, TET2 mutations have now been described in other myeloid neoplasms, such as de novo AML (12%) and chronic myelomonocytic leukemia (CMML; 42%–46%) (Abdel-Wahab et al., 2009; Smith et al., 2010). Here, TET2 is linked to myeloid neoplasm.